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POLISH GUIDELINES FOR COSTING IN
PHARMACOECONOMIC EVALUATION IN
COMPARISON TO EXISTING GUIDANCE FOR
COSTING IN OTHER COUNTRIES
Orlewska E1, Mierzejewski P2, Cel M1
1National Institute of Public Health, Warsaw, Poland; 2Agency
for Registration of Medicinal Products, Medicinal Devices &
Biocides, Warsaw, Poland
OBJECTIVES: Standardisation of costs is an important
topic within the methodology of economic evaluation.
National guidelines, that formulate the formal require-
ments for studies to be considered when deciding on 
the reimbursement of new medical therapies, are rather
global with respect to costing. In an attempt to further
standardise the costing methods some countries have
issued additional guidelines for cost calculations. The aim
of this study is to compare project of Polish guidelines for
costing with existing international guidance, highlighting
areas of agreement and dissent. METHODS: Existing
guidelines for costing were reviewed, analysed and 
comparison between they and their Polish counterpart
was subsequently undertaken. RESULTS: Guidelines for
costing in pharmacoeconomic evaluations have been
issued in Australia, Canada and the Netherlands. The
Australian costing guide provides an extensive list with
standard costs of hospital services. The use of these stan-
dard costs is obligatory in the case of formal appraisal
studies for new medications. The Canadian guidance pre-
sents basic principles and methods only and does not yet
present a standard cost list. The Dutch manual strikes the
balance between guidance mentioned above and with the
introduction of standard values and the way the standard
costs are treated introduces some new elements to stan-
dardisation of costs in economic evaluations. In Polish
project basic principles, methods for measurement and
valuation and reporting of costs are described. The 
standard values and costs are presented and recom-
mended for studies that support submissions to acquire
reimbursement. Standard costs are calculated as weighted
mean, maximum and minimum values based on available
data from sick founds and are as patient- and disease-spe-
ciﬁc as possible. CONCLUSIONS: The guidelines for
costing ﬁt with current practice and the availability of
data in each country. They contribute to the comparabil-
ity and generalisability of economic evaluations and can
deliver beneﬁt for healthcare decision makers.
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SOURCES OF VARIATION IN DRUG COSTS
AMONG STATE MEDICAID PROGRAMS
Brown J, Menzin J, Friedman M
Boston Health Economics, Inc, Waltham, MA, USA
OBJECTIVE: Drug spending is the fastest growing 
component of state Medicaid budgets. This study assesses
the extent of state variation in Medicaid drug spending
among all 50 states in 2001. METHODS: Data on 
Medicaid drug cost, users, and number of prescriptions
were compiled for 2001 for all 50 states and evaluated
by class and product. Levels of drug use and spending
were compared across states and expressed on a per-user
basis. RESULTS: Medicaid drug expenditures totaled
almost $25 billion in 2001, more than double the outlay
in 1996; drugs now account for approximately 12% of
Medicaid spending. Nationwide, the top 5 drug classes
(antipsychotics, antidepressants, gastrointestinal agents,
anticonvulsants, and antivirals) accounted for 36% of
drug expenditures, and the top 5 drugs accounted for
16% of total expenditures. The average cost per user was
about $1200 across all states. This ranged from more
than $2000 for Connecticut ($2732), New Jersey
($2159), and Rhode Island ($2130) to less than $800 for
Delaware ($756), Texas ($743), Wyoming ($714), New
Hampshire ($683), and Maryland ($616). The number of
prescriptions dispensed rather than the average cost per
prescription largely drove the differences in cost per user.
The 10 states with the highest per-user cost averaged 33
prescriptions per user, compared to an overall average of
22, and an average of 15 for the bottom 10 states. The
average cost per prescription was $53 for the 10 states
with the highest per-user cost and $51 for the bottom 
10 states. CONCLUSIONS: The number of prescriptions
per user, and not the cost per prescription, drives a four-
fold variation among states in the average prescription
drug cost per beneﬁciary. Explanatory factors should be
explored, such as population density, state drug cost 
containment strategies, disease epidemiology, and state
health and social policies.
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INCREASED HEALTHCARE UTILIZATION FOR
THE ELDERLY DUE TO INAPPROPRIATE
PRESCRIPTION USE
Fu AZ, Liu GG
University of North Carolina at Chapel Hill, Chapel Hill,
NC, USA
OBJECTIVE: Inappropriate prescribing can cause signif-
icant adverse events for all age groups. It perhaps would
be most costly when it happens to the elderly in particu-
lar. Most existing studies explored the high prevalence
and demographic variables as risk factors of inappropri-
ate prescribing. This study examines the healthcare cost
utilization outcomes of inappropriate drug use by the
elderly at the national level. METHOD: Inappropriate
medications were deﬁned by well-accepted Beers explicit
criteria. OLS and negative binomial models were
employed to estimate the functions with different depen-
dent variables using the 1996 Medical Expenditure Panel
Survey (MEPS), a national representative sample of the
non-institutionalized populations. In order to generalize
the result to the whole US nation, complex survey sample
design was adjusted in modeling. RESULTS: Compared
with elderly using proper medications, inappropriate pre-
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scription use alone increases the total health expenditure
by 17.4 percent (p < 0.05). It also increases the numbers
of outpatient visit, emergency room visit, and hospital
discharge by 0.23 (p < 0.001), 0.38 (p < 0.01), 0.23 (p =
0.05) respectively per person. Moreover, other predic-
tive variables of healthcare expenditure and utilization
include poor health status, chronic diseases, and total
number of medication use. CONCLUSION: This study
identiﬁed increased healthcare resources with elderly pop-
ulation due to inappropriate prescription use. It suggests
the necessity of health policy to improve medication use
in the aged group in an effort to save healthcare dollars
while maintaining quality of care.
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PRESCRIPTION DRUG UTILIZATION PATTERNS
AND CHARACTERISTICS OF RETAIL AND MAIL
ORDER PHARMACY UTILIZERS
Yokoyama KK,Yu W
WellPoint Pharmacy Management, West Hills, CA, USA
OBJECTIVE: To characterize patient demographics and
drug utilization patterns for members who utilize retail
and mail order pharmacies in managed care. METHODS:
Pharmacy claims data from March 1 to May 31, 2002 in
2 large health plans with over 1 and 2 million members,
respectively, were extracted. Prescription utilization data
statistics were stratiﬁed by drug dispensing channel (e.g.,
retail or mail order pharmacy). Utilizing member charac-
teristics (e.g., age, sex) were evaluated by therapeutic
class. Disease state prevalence of retail and mail order 
utilizing members were also compared. RESULTS:
Approximately 2% of enrolled members ﬁlled at least 1
prescription at a mail order pharmacy, while 30% ﬁlled
prescriptions at retail pharmacies. Mail order utilizers
tended to be older than retail utilizers, with 57% and
31% of prescriptions for patients over age 55, respec-
tively. Sex by prescription volume was 38% male and
62% female for both dispensing channels. The rate of
mail order penetration varied by disease state and 
therapeutic class. The top four drug classes, as ranked by
prescription volume, for mail order pharmacies were 
antihypertensives, antihyperlipidemics, estrogens, and
antidepressants and for retail pharmacies were antihy-
pertensives, cough/cold/allergy, anti-infectives, and anal-
gesics. Generic utilization was lower for mail order versus
retail pharmacies (32% and 43%, respectively). Prescrip-
tion volume per utilizing member per month was 1.35
and 2.45 and average days supply per prescription was
69.8 and 23.3 for mail order and retail, respectively.
CONCLUSIONS: Patient demographics and prescription
utilization patterns among retail and mail order utilizers
differed. Development of quality improvement programs
to modify prescription utilization behavior should take
these differences into consideration.
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DOCUMENTING THE RESULTS OF CLINICAL
INTERVENTIONS BY PHARMACISTS IN AN
AMBULATORY SETTING
Calvillo JP1, Lake-Wallace SE2, Hayes D1, Rice GK2,
Kulkarni AS1, Sansgiry SS1
1University of Houston, Houston,TX, USA; 2Kelsey Seybold
Clinics, Houston,TX, USA
OBJECTIVES: The aims of this study were to document
the number of clinical interventions conducted by 
pharmacists in an ambulatory setting and determine their
effectiveness. METHODS: A pharmacy documentation
form was developed and distributed to all Kelsey Seybold
pharmacies in the Houston area. Kelsey Seybold Clinics
is one of the largest IPA in the region. Pharmacists 
completed this form whenever they performed an 
activity outside the normal procedures required to ﬁll a
prescription. The form was designed to record ﬁve main
activities categorized as: interventions, therapeutic 
interchanges, medication errors, adverse drug reactions
and drug information questions. The pharmacists also
recorded actions they took, recommendations made, 
and the results of the intervention. The time taken by the
pharmacist to perform these interventions was also
recorded along with demographic information of the
patients. Data were coded and analyzed using SAS statis-
tical package at a set priori signiﬁcance level of 0.05.
Descriptive and correlation analysis were carried out on
the data collected. RESULTS: A total of 982 completed
forms were obtained for a period of 6 months
(May–October 2002). Most interventions (38.9%) were
completed within 5 minutes and 30% were completed
between 5 to 10 minutes. Pharmacists spent majority of
their time on intervention activities (76.27%). Of the 749
interventions classiﬁed, they were categorized as thera-
peutic (14.98%), prescriptions (41.21%), insurance
(40.07%), and compliance types (3.75%). Out of the 206
recommendations made by the pharmacists, 96% were
accepted by the physicians. Interventions resulted in 30%
of the drugs being clariﬁed before being dispensed, while
an additional 47% were changed before being dispensed.
A negative correlation was seen between prescription
volume and interventions. CONCLUSIONS: Pharmacists
performed numerous interventions to maximize drug
therapy outcomes. Intervention by pharmacists resulted
in enhancing appropriate drug use thus reducing cost.
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PHARMACISTS’ UTILIZATION AND
PERCEPTIONS OF DRUG INTERACTION
PROGRAM WARNINGS
Cofﬁndaffer JW1, Miller K2, Kavookjian J1, Makela E1
1West Virginia University School of Pharmacy, Morgantown,
WV, USA; 2Johns Hopkins University Hospital, Baltimore, MD,
USA
OBJECTIVES: Recent studies suggest that drug-drug
interaction messages ignored by pharmacists raise con-
